Obstetric and Gynecologic Imaging

How Should You Image Clinically Suspected Recurrent Vulvar Cancer After Treatment?

·
How Should You Image Clinically Suspected Recurrent Vulvar Cancer After Treatment?

A 68-year-old woman, two years post-treatment for Stage II vulvar squamous cell carcinoma, presents to your gynecologic oncology clinic. Her initial treatment involved a radical vulvectomy and bilateral inguinal lymphadenectomy. Today, she points to a new, firm, 1.5 cm nodule near the surgical scar, accompanied by a sense of fullness in her right groin. The physical exam is highly suspicious for recurrence. You need to confirm this suspicion, delineate the extent of local disease, and evaluate for regional nodal or distant metastatic spread before determining the next therapeutic steps. This article details the American College of Radiology (ACR) guided imaging workflow for this specific clinical challenge. For this scenario—post-treatment assessment of clinically suspected recurrence of known vulvar cancer—the ACR rates `MRI pelvis without and with IV contrast` as Usually Appropriate.

Who Fits This Clinical Scenario for Suspected Vulvar Cancer Recurrence?

This guidance is specifically for patients with a confirmed history of treated vulvar cancer who now present with new signs or symptoms concerning for recurrence. This includes clinical findings such as:

  • A new palpable nodule, mass, or ulceration at the site of the primary tumor or along surgical scars.
  • Persistent or new-onset pain, pruritus, or bleeding in the vulvar or perineal region.
  • Unexplained inguinal, pelvic, or lower extremity lymphedema.
  • A palpable or enlarging groin lymph node.

This workflow is predicated on a prior diagnosis and treatment course. It is crucial to distinguish this scenario from others that require a different imaging approach. This guidance does not apply to:

  • Patients undergoing initial staging: The imaging workup for a newly diagnosed, untreated vulvar cancer is different. For example, this workflow should not be used for the initial staging of a primary tumor that is less than or equal to 4 cm or a larger tumor being evaluated for the first time.
  • Asymptomatic routine surveillance: This article addresses the workup of clinically suspected recurrence, not routine, scheduled follow-up imaging in an asymptomatic patient.

Correctly identifying the patient’s clinical context ensures the most appropriate and highest-yield imaging study is selected.

What Diagnoses Are You Working Up in This Scenario?

When a patient presents with symptoms suggestive of recurrence, imaging serves to confirm the diagnosis and define its extent. The differential diagnosis is focused but includes critical mimics that must be excluded.

The primary and most urgent consideration is locoregional recurrence of vulvar cancer. Recurrence can manifest as a mass in the vulva or perineum, or as metastatic involvement of the inguinal, pelvic, or obturator lymph nodes. Imaging is essential to determine if the disease is confined locally, which may be amenable to salvage surgery or radiation, or if it has spread regionally.

A key alternative diagnosis is post-treatment change. Surgical scarring, fibrosis from radiation therapy, and fat necrosis can all form firm, palpable nodules that are indistinguishable from recurrent tumors on physical examination alone. High-resolution imaging is the primary non-invasive tool to differentiate these benign post-therapeutic changes from active malignancy.

Less commonly, inguinal fullness or a palpable groin mass may represent a lymphocele or abscess. These are benign post-surgical complications that can mimic nodal recurrence. A lymphocele is a collection of lymphatic fluid, while an abscess would present with associated inflammatory signs. Imaging can accurately characterize these fluid collections.

Finally, while less probable, a second primary malignancy must be considered. The development of a new, unrelated cancer in the pelvis or inguinal region is possible and would have significant implications for management.

Why Is MRI of the Pelvis Without and With IV Contrast the Recommended Study?

For evaluating suspected local recurrence of vulvar cancer, `MRI pelvis without and with IV contrast` is rated Usually Appropriate by the ACR due to its superior soft-tissue characterization in the complex post-treatment pelvis.

The primary advantage of MRI is its ability to distinguish recurrent tumor from post-surgical scar tissue and radiation-induced fibrosis. On T2-weighted sequences, recurrent tumors typically demonstrate intermediate to high signal intensity, whereas fibrosis appears dark or low-signal. Following the administration of intravenous gadolinium-based contrast, viable tumor tissue usually enhances avidly, further differentiating it from non-enhancing scar. This level of detail is critical for surgical planning.

While MRI is the top-rated study for local assessment, two other modalities are also rated Usually Appropriate and serve complementary roles, particularly for assessing distant disease:

  • CT chest abdomen pelvis with IV contrast: This study is excellent for evaluating the lungs, liver, and distant lymph node basins, which are common sites of metastasis. While it can detect bulky pelvic recurrence, its ability to resolve subtle disease within a surgically altered and irradiated field is generally inferior to MRI. It carries a significant radiation dose (☢☢☢☢ 10-30 mSv).
  • FDG-PET/CT skull base to mid-thigh: This powerful functional imaging modality detects metabolically active cancer cells throughout the body. It is highly sensitive for identifying occult nodal and distant metastases that may not be apparent on anatomic imaging alone. However, its spatial resolution for local disease is lower than MRI, and it can be prone to false positives from post-treatment inflammation. It also involves a high radiation dose (☢☢☢☢ 10-30 mSv).

In contrast, an `MRI pelvis without IV contrast` is rated only May be appropriate. The lack of contrast significantly limits the ability to characterize enhancing tumor tissue, making it much harder to differentiate recurrence from benign post-treatment changes. For this reason, contrast is essential unless a strong contraindication exists. MRI offers the distinct benefit of providing detailed pelvic anatomy without using ionizing radiation (O 0 mSv). When ordering, be sure to provide a detailed clinical history, including prior treatments and the specific location of concern, to allow the radiology team to tailor the imaging protocol for the highest diagnostic yield.

What’s Next After MRI of the Pelvis? Downstream Workflow

The results of the pelvic MRI will guide the subsequent clinical management and create a clear decision-making pathway.

If the MRI is positive for locoregional recurrence: The next step is almost always a biopsy of the suspicious lesion to obtain histologic confirmation. Once recurrence is confirmed, the patient’s case should be discussed at a multidisciplinary tumor board. Treatment options will depend on the extent of disease and prior therapies but may include salvage surgery (e.g., pelvic exenteration), re-irradiation, or systemic chemotherapy/immunotherapy. If the MRI also suggests distant disease, a whole-body staging study like FDG-PET/CT or a diagnostic CT of the chest, abdomen, and pelvis is warranted to fully define the disease burden.

If the MRI is negative for recurrence: When the MRI confidently identifies the palpable finding as benign post-treatment change (e.g., scar, fibrosis), the patient can typically return to their standard surveillance schedule. This provides reassurance and helps avoid an unnecessary invasive biopsy.

If the MRI is indeterminate or equivocal: An indeterminate finding presents a clinical challenge. In this situation, several options exist. A short-interval follow-up MRI in 6-12 weeks can assess for stability or growth. Alternatively, if clinical suspicion remains high, one might proceed directly to an image-guided or excisional biopsy. An FDG-PET/CT can also be a valuable problem-solving tool, as a metabolically active (“hot”) lesion is highly suspicious for malignancy, while a metabolically inactive (“cold”) lesion is more likely benign.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for suspected recurrent vulvar cancer requires careful attention to detail to avoid common missteps.

  • Underestimating post-treatment changes: Do not rely solely on physical exam. Fibrosis and scar tissue can feel identical to a recurrent nodule, making high-quality imaging essential for differentiation.
  • Ordering a non-contrast study: For this indication, ordering a pelvic MRI or CT without IV contrast severely limits diagnostic capability. The enhancement pattern is a key feature for identifying viable tumors.
  • Incomplete staging: A confirmed local recurrence necessitates a full evaluation for distant disease. Focusing only on the pelvis without assessing the chest and abdomen can lead to under-staging and suboptimal treatment planning.
  • Ignoring patient factors: Remember to consider contraindications to MRI (e.g., incompatible implants) or IV contrast (e.g., severe renal impairment) and select the next best alternative, such as CT or PET/CT, in consultation with a radiologist.

If imaging findings are equivocal or discordant with a high degree of clinical suspicion, escalate the case to a gynecologic oncology multidisciplinary tumor board. Collaborative input from gynecologic oncology, radiation oncology, pathology, and radiology is invaluable in complex cases.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to this topic, please consult our parent guide. Additional GigHz resources can help you apply these guidelines in your daily practice.

Frequently Asked Questions

Why is MRI preferred over CT for evaluating the local recurrence site?

MRI is preferred for assessing the primary site due to its superior soft-tissue contrast resolution. This allows it to better differentiate recurrent tumor from benign post-treatment changes like surgical scarring and radiation fibrosis, which can be difficult to distinguish on CT.

If the MRI is positive, is a biopsy always necessary?

Yes, in nearly all cases. Even with imaging findings highly suggestive of recurrence, histologic confirmation via biopsy is the standard of care before initiating further treatment, such as salvage surgery, radiation, or systemic therapy.

When should I order an FDG-PET/CT instead of or in addition to an MRI?

FDG-PET/CT is also rated ‘Usually Appropriate’ and is particularly valuable for whole-body staging. It should be considered when there is a high suspicion of regional or distant metastatic disease, to resolve equivocal findings on MRI or CT, or as a comprehensive staging tool after a local recurrence has been biopsy-proven.

What if my patient has a contraindication to MRI, like a pacemaker?

If a patient cannot undergo an MRI, a CT of the abdomen and pelvis with IV contrast is a suitable alternative for assessing the pelvis and is also excellent for evaluating distant disease. While its local soft-tissue detail is less than MRI, it is often sufficient to identify bulky recurrence.

Does a negative MRI completely rule out recurrent vulvar cancer?

A high-quality negative MRI is very reassuring and has a high negative predictive value. However, no imaging test is perfect. If there is strong clinical suspicion despite a negative MRI (e.g., a progressively growing or ulcerating lesion), a direct biopsy of the area of concern may still be warranted.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026